Cargando…
Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas
Human cytomegalovirus (HCMV) is the leading viral cause of congenital disease and permanent birth defects worldwide. Although the development of an effective vaccine is a public health priority, no vaccines are approved. Among the major antigenic targets are glycoproteins in the virion envelope, inc...
Autores principales: | Tabata, Takako, Petitt, Matthew, Li, Julia, Chi, Xiaoyuan, Chen, Wei, Yurgelonis, Irina, Wellnitz, Sabine, Bredl, Simon, Vicente, Tiago, Yang, Xinzhen, Dormitzer, Philip R., Pereira, Lenore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315547/ https://www.ncbi.nlm.nih.gov/pubmed/35891239 http://dx.doi.org/10.3390/vaccines10071074 |
Ejemplares similares
-
Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas
por: Tabata, Takako, et al.
Publicado: (2019) -
HCMV Infection of Human Trophoblast Progenitor Cells of the Placenta Is Neutralized by a Human Monoclonal Antibody to Glycoprotein B and Not by Antibodies to the Pentamer Complex
por: Zydek, Martin, et al.
Publicado: (2014) -
Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion
por: Liu, Yuhang, et al.
Publicado: (2021) -
Transfer of meropenem in the ex vivo human placenta perfusion model.
por: Hnat, Michael, et al.
Publicado: (2005) -
Human placenta as an ex vivo vascular model for neurointerventional research
por: Kwok, John Ching Kwong, et al.
Publicado: (2014)